GlassScriptPhysician profile
Misti Hedgepeth
NPI 1649753039
$11,823.60
in general payments reported to CMS, 2019-2025
66 companies · $3,037 in 2025
The $3,037 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.43 · 2022: $99.76 · 2023: $3,047 · 2024: $5,581 · 2025: $3,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,760 · Honoraria: $1,764 · Travel and Lodging: $784 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,760.31 |
| Honoraria | $1,764.00 |
| Travel and Lodging | $783.87 |
| Education | $357.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $3,090.66 | 2023-2024 | Monoferric |
| Merck Sharp & Dohme LLC | $674.83 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Pfizer INC. | $568.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $558.92 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $510.54 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $395.67 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $288.13 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Beigene USA, INC. | $282.12 | 2023-2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $277.34 | 2023-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $273.64 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $270.32 | 2024-2025 | |
| Astellas Pharma US INC | $261.13 | 2023-2025 | Xtandi, Vyloy, Padcev |
| E.R. Squibb & Sons, L.L.C. | $237.35 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $206.81 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.98 | 2023-2025 | Jardiance, Gilotrif |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $185.21 | 2023-2025 | Clonoseq |
| Emd Serono, INC. | $178.44 | 2023-2024 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $178.38 | 2023-2025 | |
| Genentech USA, INC. | $175.40 | 2023-2025 | Venclexta, Polivy |
| Eisai INC. | $167.38 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.42 | 2023-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Aveo Pharmaceuticals, INC. | $164.07 | 2024-2025 | |
| Array Biopharma INC | $163.66 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Exelixis INC. | $144.71 | 2023-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $141.24 | 2023-2025 | Libtayo |
| Genzyme Corporation | $125.52 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $112.80 | 2024-2025 | Somatuline Depot, Onivyde, Tazverik |
| Itamar Medical INC | $102.27 | 2024 | Watchpatone |
| Jazz Pharmaceuticals INC. | $101.04 | 2023-2024 | Zepzelca |
| Genmab U.S., INC. | $97.84 | 2023-2025 | Epkinly, Tivdak |
| Sanofi-Aventis U.S. LLC | $95.00 | 2023 | |
| Stemline Therapeutics INC. | $94.47 | 2023-2025 | Orserdu |
| Pharmaessentia USA Corporation | $92.24 | 2023-2025 | Besremi |
| Abbvie INC. | $87.23 | 2024-2025 | |
| Lilly USA, LLC | $82.11 | 2023-2025 | Jaypirca, Verzenio |
| Puma Biotechnology, INC. | $82.07 | 2023-2025 | |
| Seagen INC. | $72.17 | 2023 | Tukysa, Adcetris |
| Beone Medicines USA, INC. | $52.96 | 2025 | Tevimbra, Brukinsa |
| Sobi, INC | $50.18 | 2024 | |
| Mirati Therapeutics, INC. | $49.68 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $49.35 | 2023-2024 | |
| Abbott Laboratories | $47.94 | 2024-2025 | Assurity, Gallant |
| Geron Corporation | $44.07 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $43.74 | 2025 | Provenge |
| Taiho Oncology, INC. | $42.38 | 2023 | |
| Rigel Pharmaceuticals, INC. | $41.59 | 2023-2024 | Tavalisse, Rezlidhia |
| Morphosys, US INC. | $40.02 | 2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $38.88 | 2023-2025 | Xpovio |
| Coherus Oncology, INC. | $37.48 | 2024 | |
| Alnylam Pharmaceuticals INC. | $36.18 | 2023 | Givlaari |
| Janssen Pharmaceuticals, INC | $35.66 | 2023 | Xarelto |
| Blueprint Medicines Corporation | $32.67 | 2023 | Ayvakit |
| Spectrum Pharmaceuticals INC. | $32.10 | 2024 | Rolvedon |
| Shield Therapeutics INC | $31.20 | 2024 | |
| Progenics Pharmaceuticals, INC. | $30.85 | 2023 | Pylarify |
| Servier Pharmaceuticals LLC | $23.13 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $22.76 | 2021 | |
| Siemens Medical Solutions USA, INC. | $22.60 | 2024 | Truebeam |
| Azurity Pharmaceuticals, INC. | $20.43 | 2025 | Danziten |
| Celltrion USA INC. | $19.30 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $18.91 | 2025 | |
| Caris Mpi, INC. | $16.00 | 2025 | Mi Cancer Seek |
| Tolmar, INC. | $15.12 | 2023 | |
| Kite Pharma, INC. | $13.96 | 2025 | Yescarta |
| Ferring Pharmaceuticals INC. | $13.76 | 2025 | Adstiladrin |
| Pharmaand Gmbh | $8.07 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misti Hedgepeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.